secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001628280-25-021314
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy
----------------------------------------------------------------------------

- Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.
- Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.
- Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.
- Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.
- Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/0001628280-25-021314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/mdgl-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-021314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer